Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Nephros, Inc. Fourth Quarter 2025 Earnings Call - 33% Revenue Growth, Services and Education to Drive Recurring Revenue
Nephros closed 2025 with clear top-line momentum, reporting $18.8 million in revenue, up 33% year over year, and roughly $1.2 million in net income, its second consecutive profitable year. Active cust...
- Full-year 2025 revenue $18.8 million, up 33% versus 2024; Q4 2025 revenue $4.7 million, up 22% year over year.
- Net income for FY2025 approximately $1.2 million, marking the second consecutive year of profitability and the only two profitable years in company history.
- Active customer sites at year-end 2025 were 1,681, up from just over 1,500 at the end of 2024.
- +12 more takeaways
Inovio Pharmaceuticals Fourth Quarter 2025 Earnings Call - BLA for INO-3107 Accepted but FDA Flags Accelerated Approval Eligibility; Meeting Pending Ahead of Oct 30 PDUFA
Inovio’s headline is clear and precarious. The FDA has accepted the company’s BLA for INO-3107 in recurrent respiratory papillomatosis for review under the Accelerated Approval Program, with a PDUFA t...
- FDA accepted Inovio's BLA for INO-3107 under the Accelerated Approval Program with a standard 10-month review and a PDUFA target date of October 30, 2026.
- During the 60-day filing review the FDA flagged a preliminary conclusion that Inovio had not provided adequate information to justify Accelerated Approval eligibility, creating a material open issue.
- Inovio submitted an assessment aid and an sBLA in February to expand its rationale for accelerated approval and is awaiting a scheduled meeting with the FDA to resolve eligibility questions; meanwhile the BLA remains under active review.
- +15 more takeaways
Vaxart Q4 2025 Earnings Call - Dynavax Pact Validates Platform, Sentinel Cohort Safety Readout Early Q2 2026
Vaxart used the quarter to cement a high-profile tie-up for its oral COVID-19 pill and to publish encouraging early norovirus biology, while reminding investors the company still runs on a finite runw...
- Dynavax collaboration signed Nov 2025 produced $25 million upfront and a $5 million equity investment, considered validation of Vaxart’s oral platform.
- Sanofi completed its acquisition of Dynavax on Feb 10, 2026, and Vaxart reports productive interactions with Dynavax now operating as a Sanofi company.
- Under the Dynavax deal Vaxart can receive an additional $50 million if Dynavax elects to continue after submission of Phase 2B data to the FDA, plus up to approximately $195 million in regulatory milestones, $425 million in sales milestones, and tiered royalties in the low to mid-teens, totaling potential value near $700 million.
- +12 more takeaways
Funko Q4 2025 Earnings Call - Momentum Into 2026: Better-than-expected Q4, guidance for flat to +3% sales and $70-80M adjusted EBITDA
Funko closed Q4 2025 with stronger-than-expected results and margin momentum, reporting $273 million in net sales, 41% gross margin, and $23 million of adjusted EBITDA. Management points to faster pro...
- Q4 net sales were $273 million, up 9% sequentially and above company expectations.
- Gross margin for Q4 was 41%, and Funko has been above 40% in seven of the last eight quarters.
- Q4 adjusted EBITDA was $23 million, at the high end of guidance; SG&A was $91 million, down 12% year-over-year.
- +13 more takeaways
Quest Resource Holding Corporation Q4 2025 Earnings Call - Industrial Volume Drop Masks Operational Gains, Cash and Debt Moves Buy Time
Quest reported a pronounced slowdown in Q4 as industrial volumes and a prior mall divestiture drove revenue to $58.9 million, down 16% year-over-year and 7% sequentially. Management stressed that volu...
- Revenue of $58.9 million in Q4, down 16% year-over-year and 7% sequentially, driven primarily by weaker industrial volumes and a divested mall-related business.
- Industrial and mall divestiture together reduced quarterly revenue by $10.7 million versus last year; excluding those headwinds, the rest of the business grew modestly by $7.4 million, or about 5% year-over-year.
- Gross profit was $9.1 million in Q4, down 15% year-over-year and 21% sequentially, producing a gross margin of 15.5%.
- +12 more takeaways
Karat Packaging Q4 2025 Earnings Call - Paper bag ramp and tariff tailwinds set stage for low double-digit growth
Karat Packaging closed Q4 2025 with a clear growth story under pressure. Net sales rose 13.7% to $115.6 million on double-digit volume across major markets and pricing that turned positive for the fir...
- Net sales grew 13.7% year over year in Q4 2025 to $115.6 million, driven by strong double-digit volume growth across all major markets and pricing that turned positive for the first time since early 2023.
- Gross margin fell to 34.0% in Q4 2025 from 39.2% a year earlier, primarily due to a $8.4 million increase in duty and tariff costs and higher import-related expenses; import costs rose to 14.5% of sales from 8.3% in the prior-year quarter.
- Management expects tariff relief and a stabilized USD/NTD exchange rate to begin providing margin tailwinds starting in Q2 2026, and they forecast full-year 2026 gross margin and adjusted EBITDA margin to improve year over year under the current tariff environment.
- +12 more takeaways
Shimmick Corporation Q4 2025 Earnings Call - Margin Turnaround Driven by Non-Core Wind Down and Backlog Growth
Shimmick closed 2025 with a clear, measurable pivot. Revenue held roughly flat at $493 million, but the mix shifted sharply toward higher‑margin, strategic work: Shimmick projects rose to $395 million...
- 2025 was a turning point: consolidated revenue $493 million, full‑year Adjusted EBITDA $5 million versus -$61 million in 2024, and adjusted net loss narrowed to -$15 million from -$81 million in 2024.
- Shimmick projects now drive the company: Shimmick project revenue was $395 million (about 75% of total revenue) and expanded project gross margin to 10% for 2025, up 400 basis points versus 2024.
- Legacy non‑core work shrinking rapidly: non‑core revenue fell to $96 million in 2025 from $125 million in 2024, and management says non‑core was roughly 90% complete at year‑end and about 11% of backlog, with little expected to carry into 2027.
- +12 more takeaways
Heritage Global Inc. Q4 2025 Earnings Call - DebtX Acquisition Positioned to Be Accretive as Company Pushes for 2026 'Needle Mover' Year
Heritage Global closed 2025 profitable but subdued, with Q4 consolidated operating income of roughly $0.8 million (down from $1.5 million a year ago) and adjusted EBITDA of $1.1 million versus $2.1 mi...
- DebtX acquisition completed, integration described as smooth; management expects the deal to be accretive on operating income and net income, though with quarter-to-quarter variability.
- Consolidated operating income for Q4 2025 was approximately $0.8 million versus $1.5 million in Q4 2024; Q4 included about $0.4 million of M&A due diligence expenses.
- Revenue increased to $11.9 million in Q4 2025 from $10.8 million a year ago, but adjusted EBITDA fell to $1.1 million from $2.1 million.
- +9 more takeaways
HeartBeam Q4 2025 Earnings Call - FDA 510(k) Clearance Enables Limited Commercial Launch and Multi-Front Expansion
HeartBeam closed 2025 with a meaningful regulatory milestone, FDA 510(k) clearance of its 12-lead synthesis software, and a narrowly focused commercial rollout aimed at concierge and preventive cardio...
- FDA milestone: HeartBeam received 510(k) clearance in December 2025 for its 12-lead synthesis software for arrhythmia assessment, building on the HeartBeam System 510(k) from December 2024.
- Regulatory agility: The company overturned an initial NSE letter from the FDA in about 2.5 weeks, underscoring an active dialogue with regulators.
- Limited commercial launch: Management is initiating a targeted rollout in concierge cardiology and executive health, starting with anchor customer ClearCardio.
- +16 more takeaways
The Beauty Health Company Q4 2025 Earnings Call - Execution year to unlock installed-base utilization; targeting growth in 2027
New CEO frames 2026 as an execution year: sharpen the sales engine, drive utilization across a 36,000+ HydraFacial installed base, and invest selectively in clinically differentiated boosters and a ne...
- CEO Pedro Malha, five months into the role, is importing med tech playbooks: shift from device placement to device utilization as the primary growth lever.
- Q4 revenue was $82.4 million, down 1.3% year-over-year; FY2025 revenue was $300.8 million versus $334.3 million in 2024.
- Consumables were the resilient core: Q4 consumables $57.7 million, up 1.7% year-over-year, and FY consumables $212.7 million; consumables remain roughly 70% of mix.
- +12 more takeaways